首页> 美国卫生研究院文献>International Journal of Biological Sciences >Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers
【2h】

Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers

机译:抑制超级增强剂下调基底样乳腺癌中KLF5的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The transcription factor KLF5 (Krüpple-like factor 5) is highly expressed in basal-like breast cancer (BLBC), which promotes cell proliferation, survival, migration and stemness, serving as a potential therapeutic target. In the current study, a super-enhancer (SE) was identified to be located downstream of the KLF5 gene in BLBC cell lines, HCC1806 and HCC1937. JQ-1, a BRD4 inhibitor, inhibits the expression and activity of KLF5 in both HCC1806 and HCC1937 cells in a time- and dose-dependent manner. Compound 870, an in-house BRD4 inhibitor, exhibited higher potency than JQ-1 to inhibit KLF5 and BLBC growth by arresting cells in G1 phase. Additionally, THZ1, a CDK7 inhibitor, also inhibits KLF5 and BLBC growth in a similar manner. Our findings suggested that KLF5 is regulated by SE, and modulation of SE could be an effective therapeutic strategy for treating BLBC.
机译:转录因子KLF5(Krüpple样因子5)在基底样乳腺癌(BLBC)中高度表达,可促进细胞增殖,存活,迁移和干性,可作为潜在的治疗靶点。在当前研究中,在BLBC细胞系HCC1806和HCC1937中,超级增强子(SE)被确定位于KLF5基因的下游。 BRD4抑制剂JQ-1以时间和剂量依赖性方式抑制HCC1806和HCC1937细胞中KLF5的表达和活性。内部的BRD4抑制剂化合物870通过将细胞停滞在G1期中,抑制KLF5和BLBC生长的能力比JQ-1高。此外,CDK7抑制剂THZ1也以类似方式抑制KLF5和BLBC的生长。我们的发现表明KLF5受SE调节,而SE的调节可能是治疗BLBC的有效治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号